RecruitingPhase 1NCT06465069
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Sponsor: Eli Lilly and Company
Cleveland, OH · +22 more sites
Breast Cancer clinical trials in Cleveland, OH
24 recruiting breast cancer studies with a site in Cleveland, OH.
RecruitingPhase 1NCT07310420
A Trial to Evaluate Ovarian Suppression Following Subcutaneous ZOLADEX 10.8 mg in Premenopausal Women With Early-stage and Advanced HR+ Breast Cancer
Sponsor: TerSera Therapeutics LLC
Cleveland, OH · Columbus, OH · +24 more sites
RecruitingPhase 3NCT07174336
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Sponsor: Eli Lilly and Company
Akron, OH · Canton, OH · Cleveland, OH · +126 more sites
RecruitingPhase 3NCT06790693
A Study Evaluating the Efficacy and Safety of Inavolisib Plus CDK4/6 Inhibitor and Letrozole vs Placebo + CDK4/6i and Letrozole in Participants With Endocrine-Sensitive PIK3CA-Mutated, Hormone Receptor-Positive, HER2-Negative Advanced Breast Cancer
Sponsor: Hoffmann-La Roche
Cleveland, OH · Mayfield Heights, OH · +59 more sites
RecruitingPhase 2NCT06760819
A Study to Learn More About How Well Treatment With Sevabertinib (BAY 2927088) Tablets Works and How Safe it is in Participants Who Have a Solid Tumor With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
Sponsor: Bayer
Cleveland, OH · +10 more sites
RecruitingNot applicableNCT07214532
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Sponsor: Natera, Inc.
Cleveland, OH · +48 more sites
RecruitingNot applicableNCT04362826
Study to Investigate Efficacy of a Novel Probiotic on the Bacteriome and Mycobiome of Breast Cancer
Sponsor: Case Comprehensive Cancer Center
Cleveland, OH
RecruitingPhase 3NCT06492616
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
Sponsor: Stemline Therapeutics, Inc.
Centerville, OH · Cleveland, OH · +173 more sites
RecruitingPhase not listedNCT05059444
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
Sponsor: Guardant Health, Inc.
Cincinnati, OH · Cleveland, OH · Toledo, OH · +30 more sites
RecruitingPhase 1 / Phase 2NCT06657222
First in Human Study of TUB-030 in Patients With Advanced Solid Tumors
Sponsor: Gilead Sciences
Cleveland, OH · Columbus, OH · +11 more sites
RecruitingPhase 3NCT05879926
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
Sponsor: NRG Oncology
Akron, OH · Alliance, OH · +1223 more sites
RecruitingPhase 3NCT06072612
Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.
Sponsor: BriaCell Therapeutics Corporation
Canton, OH · Cleveland, OH · +77 more sites
RecruitingPhase 2NCT06129747
Repeat Breast Conserving Surgery Followed by Daily Partial Breast Irradiation in Ipsilateral Breast
Sponsor: Case Comprehensive Cancer Center
Cleveland, OH
RecruitingPhase 3NCT05812807
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
Sponsor: Alliance for Clinical Trials in Oncology
Akron, OH · Athens, OH · Avon, OH · +825 more sites
RecruitingPhase 2NCT06184750
Finding the Best Tamoxifen Dose for Breast Cancer Risk Reduction in Premenopausal Women, RENAISSANCE Trial
Sponsor: National Cancer Institute (NCI)
Cleveland, OH · +10 more sites
RecruitingPhase 1 / Phase 2NCT05768139
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
Sponsor: Eli Lilly and Company
Cleveland, OH · Columbus, OH · +26 more sites
RecruitingPhase 1NCT04389632
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Sponsor: Seagen, a wholly owned subsidiary of Pfizer
Cleveland, OH · +105 more sites
RecruitingNot applicableNCT05677802
Feasibility Study of Biobehavioral Stress Reduction Intervention in Patients With Triple Negative Breast Cancer
Sponsor: Ohio State University Comprehensive Cancer Center
Cleveland, OH · Columbus, OH
RecruitingPhase 3NCT05696626
Evaluation of Lasofoxifene Combined With Abemaciclib Compared With Fulvestrant Combined With Abemaciclib in Locally Advanced or Metastatic ER+/HER2- Breast Cancer With an ESR1 Mutation
Sponsor: LeonaBio
Cleveland, OH · Columbus, OH · +33 more sites
RecruitingPhase 3NCT04852887
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
Sponsor: NRG Oncology
Akron, OH · Avon, OH · +809 more sites
RecruitingPhase not listedNCT03448926
The PREDICT Registry:
Sponsor: PreludeDx
Akron, OH · Cleveland, OH · Columbus, OH · +27 more sites
RecruitingPhase 3NCT06435429
A Study Comparing the Efficacy and Safety of Zanidatamab to Trastuzumab, Each in Combination With Physician's Choice Chemotherapy, for the Treatment of Participants With Metastatic HER2-positive Breast Cancer
Sponsor: Jazz Pharmaceuticals
Cincinnati, OH · Cleveland, OH · +46 more sites
RecruitingPhase 1 / Phase 2NCT06249048
Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab
Sponsor: Strand Therapeutics Inc.
Cleveland, OH · +5 more sites
RecruitingPhase 1 / Phase 2NCT05824975
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
Sponsor: GI Innovation, Inc.
Cleveland, OH · +4 more sites
Listings come from ClinicalTrials.gov and are provided for information only. Always confirm eligibility with the study team and talk with your doctor before making decisions about your care.